• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

    • 4.2.1 個別化医療の需要拡大

    • 4.2.2 医薬品不足

    • 4.2.3 老年人口が増加

  • 4.3 市場の抑制要因

    • 4.3.1 熟練した調剤薬剤師の不足

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 買い手・消費者の交渉力

    • 4.4.2 サプライヤーの交渉力

    • 4.4.3 新規参入の脅威

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場のセグメンテーション（市場規模、米ドル）

  • 5.1 治療領域別

    • 5.1.1 ペインマネジメント

    • 5.1.2 ホルモン補充

    • 5.1.3 皮膚疾患

    • 5.1.4 栄養補助食品

    • 5.1.5 その他治療エリア

  • 5.2 投与経路別

    • 5.2.1 オーラル

    • 5.2.2 トピカル

    • 5.2.3 非経口

    • 5.2.4 その他の投与経路

  • 5.3 エンドユーザー別

    • 5.3.1 ヒューマンズ

    • 5.3.2 ベテリナリー

  • 5.4 地域別

    • 5.4.1 北米

      • 5.4.1.1 米国
      • 5.4.1.2 カナダ
      • 5.4.1.3 メキシコ

    • 5.4.2 ヨーロッパ

      • 5.4.2.1 ドイツ
      • 5.4.2.2 英国
      • 5.4.2.3 フランス
      • 5.4.2.4 イタリア
      • 5.4.2.5 スペイン
      • 5.4.2.6 その他のヨーロッパ

    • 5.4.3 アジア太平洋

      • 5.4.3.1 中国
      • 5.4.3.2 日本
      • 5.4.3.3 インド
      • 5.4.3.4 オーストラリア
      • 5.4.3.5 韓国
      • 5.4.3.6 その他のアジア太平洋

    • 5.4.4 中東・アフリカ

      • 5.4.4.1 GCC地域
      • 5.4.4.2 南アフリカ
      • 5.4.4.3 その他の中東・アフリカ

    • 5.4.5 南米

      • 5.4.5.1 ブラジル
      • 5.4.5.2 アルゼンチン
      • 5.4.5.3 その他の南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 B. Braun Medical Inc

    • 6.1.2 Fagron NV

    • 6.1.3 Fresenius Kabi

    • 6.1.4 Wedgewood Pharmacy

    • 6.1.5 Clinigen Group PLC

    • 6.1.6 Dougherty's Pharmacy, Inc

    • 6.1.7 Lorraine's Pharmacy

    • 6.1.8 Rx3 Compounding Pharmacy

    • 6.1.9 Institutional Pharmacy Solutions

    • 6.1.10 Mcguff compounding pharmacy services

    • 6.1.11 Pencol Compounding Pharmacy

    • 6.1.12 ITC Compounding Pharmacy

    • 6.1.13 Valor Compounding Pharmacy, Inc

• 7 市場機会と今後の動向

The Compounding Pharmacy Market size is estimated at USD 14.31 billion in 2024, and is expected to reach USD 18.86 billion by 2029, growing at a CAGR of 5.68% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the compounding pharmacy market. Several guidelines were issued by drug regulatory authorities, such as the United States Food and Drug Administration (US FDA), regarding compounded drug use for COVID-19 patients. For instance, as per the data from the US FDA published in January 2023, it was found that the FDA advised states and drug compounders on concerns relating to drug compounding during the COVID-19 pandemic. The agency's recommendations aim to safeguard patients from harmful, ineffective, and unsatisfactory compounded medications while maintaining patient access. The data further stated that stringent regulation was followed for compounded drugs during the pandemic to avoid any complications associated with such drugs. Therefore, the pandemic had a considerable impact on the market studied. However, with the rising need for personalized medicine and the growing aging population, it is believed that the market is likely to witness strong growth in the coming years.

The key factors responsible for the market growth include increasing demand for personalized medicine, shortage of drugs, and a rising geriatric population.

The growing geriatric population is one of the leading factors for market growth. For instance, according to the report from the United Nations published in January 2023, the number of people aged over 65 or older is believed to double in the next three decades. In contrast, it is expected to reach around 1.6 billion by the year 2050. The senior population is more prone to suffer from chronic, complex, and multiple diseases simultaneously, such as cardiovascular diseases, cancer, and other chronic diseases that need personalized treatment. Hence, demand for compounding pharmacies is expected to increase to treat complex diseases in the geriatric population, driving market growth over the forecast period.

Additionally, the shortage of drugs in several countries is further likely to accelerate the compounding pharmacy market growth. For instance, according to the United States Food and Drug Administration (USFDA) data published in August 2021, the United States has faced a drug shortage problem for the last few years. The COVID-19 outbreak further worsened this scenario in the country. This shortage was due to supply chain disruption, delays & discontinuation in the manufacturing processes, quality issues, and difficulties in purchasing raw materials. Hence, drug shortage further creates opportunities for compounding pharmacies, propelling the market’s growth during the forecast period.

However, the need for skilled compounding pharmacists is expected to hinder market growth in the coming years.

Compounding Pharmacy Market Trends

Pain Management Segment is Expected to Dominate the Market During the Forecast Period.

The pain management segment is expected to account for the largest share of the market owing to the large patient base suffering from chronic pain from various diseases. Increasing accidental cases, high burden of cancer, and chronic pain cases are key factors responsible for the growth of the pain management market. For instance, according to the data published by the Health Economists in September 2021, Chronic pain costs about USD 635 billion yearly to the United States, which is greater than the annual costs of diabetes, cancer, and heart diseases. Compounding pharmacies provide drugs for effective pain management tailored for specific patients. Thus, chronic pain management is expected to contribute to the market's growth during the forecast period.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), anticonvulsants, antidepressants, topical analgesics, and opioids are the major classes of drugs that doctors prescribe for chronic pain management. Nonsteroidal anti-inflammatory drugs are available by prescription to relieve fever and pain. However, certain side effects are associated with these medications, including stomach irritation, unpleasant side effects, and unwanted flavor/route of administration. Compounding pharmacies provide alternate methods to ease consumption and cope with the side effects. Such an advantage of compounding pharmacy is expected to accelerate market growth.

North America is Expected to Hold Major Share in the Market during the Forecast Period

The compounding pharmacy industry in North America is expected to hold a significant market share during the forecast period. The presence of several compounding pharmacies, high adoption among people, and scarcity of many drugs are key factors for market growth. According to the statistics published by the International Academy of Compounding Pharmacists (IACP) in October 2021, about 56,000 compounding pharmacies were operating in the United States, of which 7,500 pharmacies provide advanced compounding services.

Several organizations are interested in the compounding pharmacy business across the United States, which is believed to contribute to the market growth. For instance, in March 2021, Osceola Capital, a lower middle-market private equity firm, announced the formation of Revelation Pharma Corp. to pursue investments and partnerships across the pharmacy compounding market in partnership with industry executives.

Similarly, in August 2021, Empower Pharmacy, a premier compounding pharmacy and FDA-registered outsourcing facility, announced its new branch opening in Houston, United States. Approximately USD 55 million was spent on this facility to enhance access to affordable and innovative pharmaceutical solutions in the North American region. Therefore, owing to the developments mentioned above in the compounding pharmacy business, the market studied is believed to witness strong growth in the region.

Compounding Pharmacy Industry Overview

The compounding pharmacy market is moderately consolidated. B. Braun, Athenex Pharma Solutions, Fresenius Kabi, Clinigen Group PLC, Dougherty's Pharmacy, Inc., Lorraine's Pharmacy, Nephron Pharmaceuticals Corporation, Rx3 Compounding Pharmacy, Institutional Pharmacy Solutions, Mcguff compounding pharmacy services, Pencol Compounding Pharmacy, ITC Compounding Pharmacy, and Valor Compounding Pharmacy are some of the key compounding pharmacies in the market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Increasing Demand of Personalized Medicine

    • 4.2.2 Shortage of Drugs

    • 4.2.3 Rising Geriatric Population

  • 4.3 Market Restraints

    • 4.3.1 Lack of Skilled Compounding Pharmacists

  • 4.4 Porter's Five Forces Analysis

    • 4.4.1 Bargaining Power of Buyers/Consumers

    • 4.4.2 Bargaining Power of Suppliers

    • 4.4.3 Threat of New Entrants

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Therapeutic Area

    • 5.1.1 Pain Management

    • 5.1.2 Hormone Replacement

    • 5.1.3 Dermal Disorders

    • 5.1.4 Nutritional Supplements

    • 5.1.5 Other Therapeutic Areas

  • 5.2 By Route of Administration

    • 5.2.1 Oral

    • 5.2.2 Topical

    • 5.2.3 Parenteral

    • 5.2.4 Other Route of Administrations

  • 5.3 By End-User

    • 5.3.1 Humans

    • 5.3.2 Veterinary

  • 5.4 Geography

    • 5.4.1 North America

      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico

    • 5.4.2 Europe

      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe

    • 5.4.3 Asia-Pacific

      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific

    • 5.4.4 Middle-East and Africa

      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa

    • 5.4.5 South America

      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 B. Braun Medical Inc

    • 6.1.2 Fagron NV

    • 6.1.3 Fresenius Kabi

    • 6.1.4 Wedgewood Pharmacy

    • 6.1.5 Clinigen Group PLC

    • 6.1.6 Dougherty's Pharmacy, Inc

    • 6.1.7 Lorraine's Pharmacy

    • 6.1.8 Rx3 Compounding Pharmacy

    • 6.1.9 Institutional Pharmacy Solutions

    • 6.1.10 Mcguff compounding pharmacy services

    • 6.1.11 Pencol Compounding Pharmacy

    • 6.1.12 ITC Compounding Pharmacy

    • 6.1.13 Valor Compounding Pharmacy, Inc

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS